Modulation of circulating inflammatory biomarkers by SGLT2 inhibitors in diabetic patients with acute myocardial infarction: A quantitative meta-analysis of laboratory evidence.

BACKGROUND: Acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM) is characterized by an exaggerated inflammatory response and adverse myocardial remodeling. Sodium-glucose cotransporter-2 inhibitors (SGLT2-I) have demonstrated cardiometabolic benefits; however, their effects on circulating inflammatory biomarkers in diabetic AMI remain inconsistent. This meta-analysis aimed to quantitatively evaluate laboratory-based evidence regarding the modulation of key inflammatory markers by SGLT2-I therapy in this high-risk population. METHODS: A systematic search of PubMed, ScienceDirect, Cochrane Library, Web of Science, CNKI, and Wanfang databases was conducted up to December 2025. Randomized controlled trials and prospective cohort studies involving T2DM patients with AMI were included. Primary laboratory endpoints were circulating inflammatory biomarkers (interleukin-6 [IL-6], high-sensitivity C-reactive protein [hs-CRP], tumor necrosis factor-a [TNF-a]). Secondary outcomes included left ventricular ejection fraction (LVEF) and major adverse cardiovascular events (MACE).